Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00706550 · ClinicalTrials.gov registry record · NA
Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects
A NA study, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- NA
- Development phase
- 107
- Enrollment target
NCT00706550 is a NA study that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 107 participants.
The verdict
NCT00706550, a NA study, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- NA
- Development phase
- 107 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the best timing for administering pneumococcal vaccine (PV) to HIV-infected adults that have CD4 cell counts of more than 200 and are not yet receiving combination antiretroviral treatment (ART). Participants in this study will be assigned by chance to receive vaccination with PV prior to starting ART or after at least 6 months of ART. Antibody levels to components of the PV will be measured at 6 months and 12 months after vaccination. The results will tell us if patients that receive PV after 6 months of ART have better response to the vaccine than those that get vaccinated prior to treatment.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL (PV) 23-valent pneumococcal polysaccharide vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2008-10 |
| Est. Completion | 2012-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00706550
The ClinicalTrials.gov registry entry for NCT00706550 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Department of Veterans Affairs, which has 632 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00706550 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00706550 about?
NCT00706550 is a clinical study titled "Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects". The purpose of this study is to evaluate the best timing for administering pneumococcal vaccine (PV) to HIV-infected adults that have CD4 cell counts of more than 200 and are not yet receiving combination antiretroviral treatment (ART). Participants in this study will be assigned by chance to receiv...
What is the current status of trial NCT00706550?
This trial is currently completed. It is a NA study. The enrollment target is 107 participants. The study started on 2008-10. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00706550?
The interventions under investigation include: Placebo (BIOLOGICAL), (PV) 23-valent pneumococcal polysaccharide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00706550?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.